Deutsche Bank Aktiengesellschaft DB Shows Resilient Core Business Despite Market Volatility Singapore Benefits from Global AI Investment Surge but Faces Geopolitical Risks Says MTI Gold and Silver Retreat Comex Precious Metals Settle Lower Amid Market Pressures Plus500 Reports 11 Quarterly Revenue Growth Reaffirms FullYear Guidance Extra EU Border Checks Suspended at Dover Potential Disruption for CrossChannel Ferry Operators and Travel Industry Fed Minutes Signal Potential Rate Hikes if Inflation Persists Amid Geopolitical Tensions Brandywine Realty Trust BDN Q1 2026 Earnings Modest Loss Surprise as Office REIT Navigates Market Headwinds NOC Q1 2026 Earnings EPS Slightly Tops Estimates as Defense Demand Holds CRAI Q1 2026 Earnings EPS Misses Estimates as Consulting Demand Softens OEC Q1 2026 Earnings Significant EPS Miss Amid Market Challenges LGIH Q1 2026 Earnings Staggering EPS Surprise of Over 1000 Exceeds Low Expectations AUGO Q1 2026 Earnings EPS Falls Short of Estimates Stock Declines Highview Merger Corp Warrants HVMCW Hold Steady at 035 as Key Levels Tighten TriNet Group TNET Gains 227 as Stock Approaches Key Resistance Level JDcom JD Dips 05 as Shares Approach Resistance Near 31 Level Kandal M Venture Limited FMFC Edges Higher Testing Key Resistance Near 04 Astrana Health Inc ASTH Rises 126 Approaching Key Resistance Level NVIDIA and Fortinet Join Forces to Protect AI Workloads in Real Time Medallion Financial Corp MFIN Q1 2026 Earnings Profitability Miss Pressures the Stock AutoNation AN Edges Higher Amid Sector Resilience Technical Levels in Focus Addus HomeCare Corporation ADUS Q1 2026 Earnings EPS Beat Partially Offsets Cautious Stock Reaction THRY Q1 2026 Earnings Significant EPS Surprise Drives Positive Stock Reaction BLDP Q1 2026 Earnings NarrowerThanExpected Loss Drives Positive Investor Sentiment ESS Q1 2026 Earnings EPS Beat Lifts Shares Amid Steady Apartment Demand DTM Q1 2026 Earnings EPS Surpasses Expectations by Nearly 10 Stock Edges Lower RYZ Q1 2026 Earnings EPS Misses Estimates by 646 Amid Challenging Conditions NervGen Pharma Q3 2025 Earnings Narrowed Loss Meets Estimates But Stock Plunges 43